Ticker | Company Name | Drug Name | Indication | NCT | Next Catalyst | Stage | FDA Status | Catalyst Date | Conference | Market Cap | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
I IVVD | Invivyd Inc. | VYD2311 - (DECLARATION) | COVID-19 | NCT06523153 | Topline Data | Phase 3 | Trial Planned | 2026-08-31 | $404.1M | $3.2M | |
R RGNX | REGENXBIO Inc. | RGX-202 - (AFFINITY DUCHENNE) | Duchenne Muscular Dystrophy (DMD) | NCT05693142 | Submission | BLA Filing | Data Released | 2026-08-31 | $403.1M | $393.0K | |
A AVTX | Avalo Therapeutics Inc. | AVTX-009 (anti-IL-1β mAb) - (LOTUS) | Hidradenitis suppurativa (HS) | NCT06603077 | Topline Data | Phase 2 | Ongoing | 2026-08-31 | $249.0M | $364.3K | |
M MMM | 3M Company | EscharEx - (VALUE) | Venous leg ulcers (VLU’s) | NCT03588130 | Interim Data | Phase 3 | Ongoing | 2026-08-31 | $77.3B | $4.5M | |
M MDWD | MediWound Ltd. | EscharEx - (VALUE) | Venous leg ulcers (VLU’s) | NCT03588130 | Interim Data | Phase 3 | Ongoing | 2026-08-31 | $213.4M | $60.1K | |
T TRDA | Entrada Therapeutics Inc. | ENTR-601-45 - (ELEVATE-45-201) | Duchenne Muscular Dystrophy | Initial Data | Phase 1/2 | Enrollment Initiation | 2026-08-31 | $439.1M | $126.0K | ||
A ANRO | Alto Neuroscience Inc. | ALTO-300 | Major Depressive Disorder (MDD) | NCT05922878 | Full Results | Phase 2b | Ongoing | 2026-08-31 | $645.0M | $354.2K | |
C CNTX | Context Therapeutics Inc. | CT-95 (mesothelin) | Solid tumors | Initial Data | Phase 1 | Enrollment Initiation | 2026-08-31 | $292.2M | $659.7K | ||
O ORIC | Oric Pharmaceuticals Inc. | ORIC-114 | Tumors - EGFR/HER2 Exon 20 Inhibitor, 1L NSCLC | NCT05315700 | Interim Data | Phase 1b | Ongoing | 2026-08-31 | $1.2B | $1.1M | |
K KPTI | Karyopharm Therapeutics Inc. | XPOVIO (selinexor) - (XPORT-EC-042) | TP53 wild-type advanced or recurrent endometrial cancer | NCT05611931 | Topline Data | Phase 3 | Ongoing | 2026-08-31 | $132.8M | $49.9K |
Rows per page
Page 1 of 21